CN1224349A - 口腔内快速崩解片剂 - Google Patents
口腔内快速崩解片剂 Download PDFInfo
- Publication number
- CN1224349A CN1224349A CN97195520.4A CN97195520A CN1224349A CN 1224349 A CN1224349 A CN 1224349A CN 97195520 A CN97195520 A CN 97195520A CN 1224349 A CN1224349 A CN 1224349A
- Authority
- CN
- China
- Prior art keywords
- tablet
- compression molding
- agent
- saccharide
- sugar alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 14
- 150000005846 sugar alcohols Chemical class 0.000 claims abstract description 13
- 238000000748 compression moulding Methods 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 23
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 235000010355 mannitol Nutrition 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 7
- 239000012752 auxiliary agent Substances 0.000 claims description 7
- 239000008101 lactose Substances 0.000 claims description 7
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 7
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 7
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 7
- 239000000314 lubricant Substances 0.000 claims description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- 239000004570 mortar (masonry) Substances 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 51
- 235000019589 hardness Nutrition 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 238000001035 drying Methods 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 241000723353 Chrysanthemum Species 0.000 description 5
- 235000007516 Chrysanthemum Nutrition 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000000465 moulding Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 4
- 229960001253 domperidone Drugs 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229940025250 camphora Drugs 0.000 description 3
- 239000010238 camphora Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000007493 shaping process Methods 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- VIROVYVQCGLCII-UHFFFAOYSA-N amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 150000003851 azoles Chemical class 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000004088 foaming agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- -1 sucrose fatty acid ester Chemical class 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WEUCDJCFJHYFRL-UHFFFAOYSA-N 1-[(4-chlorophenyl)-phenylmethyl]-4-methyl-1,4-diazepane Chemical compound C1CN(C)CCCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 WEUCDJCFJHYFRL-UHFFFAOYSA-N 0.000 description 1
- VQPBLPKQGMFEEB-UHFFFAOYSA-N 1-benzylphthalazine Chemical class N=1N=CC2=CC=CC=C2C=1CC1=CC=CC=C1 VQPBLPKQGMFEEB-UHFFFAOYSA-N 0.000 description 1
- 239000001074 1-methoxy-4-[(E)-prop-1-enyl]benzene Substances 0.000 description 1
- FEDJGPQLLNQAIY-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridazin-3-yl)oxy]acetic acid Chemical compound OC(=O)COC=1C=CC(=O)NN=1 FEDJGPQLLNQAIY-UHFFFAOYSA-N 0.000 description 1
- FIVHOHCAXWQPGC-UHFFFAOYSA-N 2-[2-(4-chlorophenoxy)acetyl]oxyethyl-dimethylazanium;chloride Chemical compound Cl.CN(C)CCOC(=O)COC1=CC=C(Cl)C=C1 FIVHOHCAXWQPGC-UHFFFAOYSA-N 0.000 description 1
- SQVIAVUSQAWMKL-UHFFFAOYSA-N 3-[2-(ethylamino)-1-hydroxyethyl]phenol Chemical compound CCNCC(O)C1=CC=CC(O)=C1 SQVIAVUSQAWMKL-UHFFFAOYSA-N 0.000 description 1
- WTJXVDPDEQKTCV-UHFFFAOYSA-N 4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2C1CC1C(N(C)C)C(=O)C(C(N)=O)=C(O)C1(O)C2=O WTJXVDPDEQKTCV-UHFFFAOYSA-N 0.000 description 1
- AZEIRPAUJXANCS-UHFFFAOYSA-N 4-ethoxybenzamide Chemical compound CCOC1=CC=C(C(N)=O)C=C1 AZEIRPAUJXANCS-UHFFFAOYSA-N 0.000 description 1
- IVVHAAOJLULJLK-YDXSIYMFSA-E Aceglutamide aluminum Chemical compound [OH-].[OH-].[OH-].[OH-].[Al+3].[Al+3].[Al+3].CC(=O)N[C@H](C([O-])=O)CCC(N)=O.CC(=O)N[C@H](C([O-])=O)CCC(N)=O.CC(=O)N[C@H](C([O-])=O)CCC(N)=O.CC(=O)N[C@H](C([O-])=O)CCC(N)=O.CC(=O)N[C@H](C([O-])=O)CCC(N)=O IVVHAAOJLULJLK-YDXSIYMFSA-E 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- BMOVQUBVGICXQN-UHFFFAOYSA-N Clinofibrate Chemical compound C1=CC(OC(C)(CC)C(O)=O)=CC=C1C1(C=2C=CC(OC(C)(CC)C(O)=O)=CC=2)CCCCC1 BMOVQUBVGICXQN-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- VMZUTJCNQWMAGF-UHFFFAOYSA-N Etizolam Chemical compound S1C(CC)=CC2=C1N1C(C)=NN=C1CN=C2C1=CC=CC=C1Cl VMZUTJCNQWMAGF-UHFFFAOYSA-N 0.000 description 1
- RXKMOPXNWTYEHI-RDRKJGRWSA-N Flunarizine hydrochloride Chemical compound Cl.Cl.C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 RXKMOPXNWTYEHI-RDRKJGRWSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- ZIIJJOPLRSCQNX-UHFFFAOYSA-N Flurazepam hydrochloride Chemical compound Cl.Cl.N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F ZIIJJOPLRSCQNX-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- WGZDBVOTUVNQFP-UHFFFAOYSA-N N-(1-phthalazinylamino)carbamic acid ethyl ester Chemical compound C1=CC=C2C(NNC(=O)OCC)=NN=CC2=C1 WGZDBVOTUVNQFP-UHFFFAOYSA-N 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- VRAHPESAMYMDQI-UHFFFAOYSA-N Nicomol Chemical compound C1CCC(COC(=O)C=2C=NC=CC=2)(COC(=O)C=2C=NC=CC=2)C(O)C1(COC(=O)C=1C=NC=CC=1)COC(=O)C1=CC=CN=C1 VRAHPESAMYMDQI-UHFFFAOYSA-N 0.000 description 1
- 206010030973 Oral discomfort Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- FCLZCOCSZQNREK-UHFFFAOYSA-N Pyrrolidine, hydrochloride Chemical compound Cl.C1CCNC1 FCLZCOCSZQNREK-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- RUJBDQSFYCKFAA-UHFFFAOYSA-N Tofisopam Chemical compound N=1N=C(C)C(CC)C2=CC(OC)=C(OC)C=C2C=1C1=CC=C(OC)C(OC)=C1 RUJBDQSFYCKFAA-UHFFFAOYSA-N 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical compound C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 229960002627 aceglutamide aluminum Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940092229 aldactone Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- WOLHOYHSEKDWQH-UHFFFAOYSA-N amantadine hydrochloride Chemical compound [Cl-].C1C(C2)CC3CC2CC1([NH3+])C3 WOLHOYHSEKDWQH-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- PECIYKGSSMCNHN-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=NC=N[C]21.O=C1N(C)C(=O)N(C)C2=NC=N[C]21 PECIYKGSSMCNHN-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 229960001301 amobarbital Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940125713 antianxiety drug Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- QZVNQOLPLYWLHQ-ZEQKJWHPSA-N benidipine Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@H]2CN(CC=3C=CC=CC=3)CCC2)=CC=CC([N+]([O-])=O)=C1 QZVNQOLPLYWLHQ-ZEQKJWHPSA-N 0.000 description 1
- 229960004916 benidipine Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- FHRSHSOEWXUORL-HDJSIYSDSA-N cetraxate Chemical compound C1C[C@@H](C[NH3+])CC[C@@H]1C(=O)OC1=CC=C(CCC([O-])=O)C=C1 FHRSHSOEWXUORL-HDJSIYSDSA-N 0.000 description 1
- 229950009533 cetraxate Drugs 0.000 description 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- MXOAEAUPQDYUQM-UHFFFAOYSA-N chlorphenesin Chemical compound OCC(O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-UHFFFAOYSA-N 0.000 description 1
- 239000000731 choleretic agent Substances 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 229960000876 cinnarizine Drugs 0.000 description 1
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 1
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 1
- 229960005132 cisapride Drugs 0.000 description 1
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- 229950003072 clinofibrate Drugs 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229960005316 diltiazem hydrochloride Drugs 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 229960005172 etilefrine hydrochloride Drugs 0.000 description 1
- 229960004404 etizolam Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229960002807 flunarizine hydrochloride Drugs 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960003628 flurazepam hydrochloride Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960005384 hydralazine hydrochloride Drugs 0.000 description 1
- ZUXNZUWOTSUBMN-UHFFFAOYSA-N hydralazine hydrochloride Chemical compound Cl.C1=CC=C2C(NN)=NN=CC2=C1 ZUXNZUWOTSUBMN-UHFFFAOYSA-N 0.000 description 1
- CFUQBFQTFMOZBK-QUCCMNQESA-N ibazocine Chemical compound C12=CC(O)=CC=C2C[C@H]2N(CC=C(C)C)CC[C@]1(C)C2(C)C CFUQBFQTFMOZBK-QUCCMNQESA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229940090589 keflex Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 150000002597 lactoses Chemical class 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 229960002983 loperamide hydrochloride Drugs 0.000 description 1
- PGYPOBZJRVSMDS-UHFFFAOYSA-N loperamide hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 PGYPOBZJRVSMDS-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 229960002421 minocycline hydrochloride Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229950001071 nicomol Drugs 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 1
- 229960001454 nitrazepam Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- BAINIUMDFURPJM-UHFFFAOYSA-N oxatomide Chemical compound O=C1NC2=CC=CC=C2N1CCCN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 BAINIUMDFURPJM-UHFFFAOYSA-N 0.000 description 1
- 229960002698 oxatomide Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 229960005065 paromomycin sulfate Drugs 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229960001749 practolol Drugs 0.000 description 1
- DURULFYMVIFBIR-UHFFFAOYSA-N practolol Chemical compound CC(C)NCC(O)COC1=CC=C(NC(C)=O)C=C1 DURULFYMVIFBIR-UHFFFAOYSA-N 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229940084026 sodium valproate Drugs 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- ZPCCSZFPOXBNDL-RSMXASMKSA-N spiramycin II Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]([C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)OC(C)=O)[C@H]1CC[C@H](N(C)C)[C@H](C)O1 ZPCCSZFPOXBNDL-RSMXASMKSA-N 0.000 description 1
- 229950006796 spiramycin ii Drugs 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004940 sulpiride Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1
- 229950001089 todralazine Drugs 0.000 description 1
- 229960002501 tofisopam Drugs 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 1
- LMJSLTNSBFUCMU-UHFFFAOYSA-N trichlormethiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(C(Cl)Cl)NS2(=O)=O LMJSLTNSBFUCMU-UHFFFAOYSA-N 0.000 description 1
- 229960004813 trichlormethiazide Drugs 0.000 description 1
- 229960001032 trihexyphenidyl Drugs 0.000 description 1
- 150000003673 urethanes Chemical class 0.000 description 1
- 229960005251 valethamate Drugs 0.000 description 1
- UPPMZCXMQRVMME-UHFFFAOYSA-N valethamate Chemical compound CC[N+](C)(CC)CCOC(=O)C(C(C)CC)C1=CC=CC=C1 UPPMZCXMQRVMME-UHFFFAOYSA-N 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
按照本发明能够提供含有平均颗粒直径30μm以下的糖醇或者糖类、活性成分和崩解剂的片剂。
Description
技术领域
本发明是关于在口腔内快速崩解的片剂。
背景技术
在药品的经口给药的剂型中,例如有片剂、胶囊剂、颗粒剂、散剂、糖浆剂等。然而,对于这些经口制剂,存在一些问题。例如,片剂和胶囊剂,对于吞咽力弱的老年人和儿童是难以服用的剂型。颗粒剂和散剂服用后在口中产生不愉快感,或者也有作为粉体进入气管和肺中的情况,并且,服用时必须有水,因此在无水的场所,往往不能服用。糖浆剂在服用时需要计量,因此较费功夫,并且,对老年人和孩子来说,不能指望正确的计量。与此相反,如果是在口腔内快速溶解或者崩解的固体成形物,就不需要花费计量的功夫,对于老年人和儿童也能够容易服用。另外,该固体成形物没有水也能够服用。像这样在口腔内快速溶解或者崩解的制剂,已经知道一些。例如,在特公昭62-50445号公报中已记载,通过冻干以含有活性成分的明胶作为主成分的水溶液,而得到固体制剂。另外,在W093/12769中已记载:通过干燥包含琼脂的悬浮液,而得到固体制剂。但是,这些制剂中存在以下问题:固形物的强度弱,很难从PTP(压紧包装,Press Through Pack)包装中挤出,需要特殊的制剂技术,需要庞大的设备投资。另外,在特开平5-271045号公报或者WO 93/15724中已记载:在包含糖类的混合物中适当地添加水、在低压下压缩成形后进行干燥的片剂调制法。但是,该方法需要特殊的制剂技术,在以湿润状态压缩时,有粉体附着在成形金属模面上的危险,因此难以适用于工业生产。
发明的公开
本发明人对不需要特殊的制剂技术、以一般的设备就能够简便且容易地调制的口腔内快速崩解片剂进行了研究。其结果发现,将含有以平均颗粒直径30μm以下的D-甘露糖醇和乳糖等的糖醇或者糖类作为主成分、活性成分和崩解剂的混合物压缩成形,得到以往的压缩成形机调制困难的、在1分钟内在口腔中快速崩解、保持实用上没有问题的硬度的口腔内快速崩解片剂。
即,本发明是关于含有平均颗粒直径30μm以下之糖醇或者糖类、活性成分和崩解剂的片剂。
另外,本发明是关于片剂的制造方法,其特征是,将含有平均颗粒直径30μm以下之糖醇或者糖类、活性成分和崩解剂的混合物压缩成形。
作为糖醇可举出在药品和食品中广泛使用的,例如D-甘露糖醇、山梨糖醇等。作为糖类可举出在药品和食品中广泛使用的,例如乳糖、葡萄糖等。使用至少1种糖醇或者糖类。
作为活性成分可举出例如下述记载的活性成分,如果是以经口给药为目的,就不加特别的限制。
<中枢神经用药>
睡眠镇静剂、抗焦虑剂…异戊巴比妥、阿尔唑仑、盐酸氟西泮、安定等。
抗癫痫剂…丙戊酸钠、硝基安定、苯妥英等。
镇痛解热消炎剂…阿司匹林、扑热息痛、布洛芬、双氯灭痛、止痛灵、吲哚美辛等。
抗帕金森氏剂…左旋多巴、盐酸金刚胺、盐酸苯海索、盐酸吡咯庚丁等。
精神神经用剂…依替唑仑、阿米替林、舒必利等。
<末梢神经系用药>
骨骼肌松弛剂…氨基甲酸氯苯甘油醚、氯美酮等。
自主神经剂…苯戊溴铵、托非索泮等。
镇痉剂…氯哇宁磷酸盐等。
<循环器官用药>
强心剂…癸烯醌、氨茶碱、盐酸乙苯福林等。
心律不齐用剂…氨酰心安、心得宁等。
利尿剂…螺旋内酯、三氯噻嗪、呋罗酰胺等。
降压剂…盐酸托酞嗪、盐酸尼力地平、盐酸肼苯哒嗪等。
血管收缩剂…甲磺酸双氢麦角胺等。
血管扩张剂…盐酸比尼地平(ベニヅピン)、盐酸硫氮卓酮、硝酸异山梨醇等。
高血脂用剂…克利贝特、尼可莫尔等。
其他…盐酸氟桂嗪、盐酸氯酯醒、肉桂苯哌嗪等。
<呼吸器官用药>
止泻剂…盐酸氯苯哌酰胺、二甲硅油等。
消化性溃疡用剂…苷菊环烃、L-谷氨酰胺、乙酰谷酰胺铝、盐酸西曲酸酯、西米替丁等。
利胆剂…胆维他、鹅脱氧胆酸等。
其他…吗丁啉、马来酸トチメブチン、胃复安、西沙必利(シサフティド)等。
<代谢性药品>
维生素剂…阿耳法钙化醇(アルフアカルシド-ル)、盐酸硫胺、维生素B12、磷酸吡哆醛制剂、丁酸维生素B2、抗坏血酸、维生素K1等。
糖尿病用剂…格利丁唑、甲苯磺丁脲等。
<过敏性用药>
抗组胺剂…盐酸高氯环嗪、富马酸吡咯醇胺、马来酸氯苯吡胺等。
其他…苯咪唑嗪、富马酸甲哌噻庚酮、盐酸卓苄酞嗪等。
<肿瘤用药>
代谢拮抗剂…氟尿嘧啶、呋喃氟尿嘧啶等。
<抗生素制剂>
硫酸巴龙霉素、羟氨苄青霉素、氯氨苄头孢菌素、头孢菌素Ⅳ、乙酰螺旋霉素、盐酸米诺环素等。
崩解剂可举出在药品和食品中广泛使用的,例如交联聚维酮、交联羧甲基纤维素钠、低取代度羟丙基纤维素等,使用至少1种崩解剂。
下面,说明本发明的片剂制造方法。
本发明的片剂,可以使用锤式粉碎机、喷射磨机等,将含有平均颗粒直径为30μm以下的糖醇或者糖类、活性成分和崩解剂的混合物造粒后,进行压缩成形而得到。另外,本发明的片剂也可以使用锤式粉碎机、喷射磨机等,在容易挥发的崩解助剂的存在下,将含有平均颗粒直径为30μm以下的糖醇或者糖类、活性成分和崩解剂的混合物造粒后,进行压缩成形,接着使崩解助剂挥发而得到。
糖醇或者糖类的使用量,在片剂中以60~95%为佳,最佳是80~95%。
活性成分的使用量随活性成分的种类、给药量等不同而不同,但在片剂中以0.01~30%为佳,最佳是0.01~10%。
崩解剂的使用量,对于在1次给药份额最好是1~30mg,在片剂中最好是1~10%。
容易挥发的崩解助剂例如可举出有升华性的樟脑、氨基甲酸乙酯、尿素、重碳酸铵、苯甲酸等,但最好是樟脑。容易挥发的崩解助剂的使用量,在片剂中以1~20%为佳,最佳是1~10%。
造粒方法以使用蒸馏水、乙醇等的湿式造粒为佳,例如使用一般的流动层造粒机、转动搅拌造粒机、挤出造粒机等进行,将造粒物干燥后,添加润滑剂进行混合,然后压缩成形。此时,作为添加剂也可以添加粘结剂、酸味剂、发泡剂、甜味剂、香料、着色剂等。润滑剂可举出硬脂酸镁、硬脂酸、硬脂醇、蔗糖脂肪酸酯、滑石、轻质二氧化硅等。粘结剂可举出羟丙基纤维素、聚乙烯吡咯烷酮、羟丙基甲基纤维素、部分皂化聚乙烯醇、甲基纤维素、支链淀粉(プルテン)等。酸味剂可举出柠檬酸、苹果酸、己二酸、抗坏血酸等。发泡剂可举出碳酸氢钠、碳酸钠、碳酸钙等。甜味剂可举出天冬糖精(Aspartame,注册商标)、糖精、甘草甜等。香料可举出柠檬、橙、菠萝、薄荷、薄荷醇等。着色剂可举出氧化铁黄、氧化铁红、タ-ル系色素等。润滑剂的使用量,在片剂中以0.01~1%为佳,最佳是0.01~0.5%。
压缩成形方法没有特别的限制,但最好使用生产率优良的旋转打片机、油压压力机或者单发打片机。在使用容易挥发的崩解助剂时,压缩成形后,通过加热等进行干燥。另外,压缩成形时,在造粒物中不含润滑剂时,也可预先将润滑剂涂布在打片机的捣杵和臼上,然后进行压缩成形,借此更加增大本发明的效果。压缩成形压力,在使用旋转打片机时,最好是300Kg以上。
按照本发明得到的片剂的形状,也可以是圆形片或者具有普通R面、糖衣R面、スミカク平面、スミマル平面、二段R面等表面形状的各种异形片。
另外,该片剂作为划有分割线的分割片也可以使用。
发明的最佳实施方式
以下,根据实施例和比较例更具体地说明本发明。比较例1
将1890g的D-甘露糖醇(东和化成:平均颗粒直径约60μm)和100g交联聚维酮(ポリプテスドンXL-10:GAF公司)放入流动层造粒干燥机(グテット公司制造,WSG-5型)中,将蒸馏水喷雾,经造粒、干燥工序,得到造粒物。在造粒物中添加10g硬脂酸镁,混合后,使用旋转型打片机(菊水制作所制造,クリ-ンプレスコレクト12型)进行压缩成形。成形条件规定为:片剂重量200mg、金属模直径8mm、平型,压缩成形压力在150、300、450、600和800Kg变化,进行打片。实施例1
预先使用喷射磨机(日本ニコ-マチツク公司制造:PJM-1-1.5型)将D-甘露糖醇(东和化成:平均颗粒直径约60μm)粉碎,得到平均颗粒直径约20μm的D-甘露糖醇。将1890g的该D-甘露糖醇粉碎品和100g交联聚维酮(ポリプテスドンXL-10:GAF公司)放入流动层造粒干燥机(クテット公司制造,WSG-5型)中,将蒸馏水喷雾,经造粒、干燥工序,得到造粒物。在造粒物中添加10g硬脂酸镁,混合后,使用旋转型打片机(菊水制作所制造,クリ-ンプレスコレクト12型)进行压缩成形。成形条件和比较例1相同。比较例2
将100g消化道运动改善剂吗丁啉、1790g乳糖(DWV公司:平均颗粒直径约80μm)和100g交联聚维酮(ポリプラスドンXL-10:GAF公司)放入流动层造粒干燥机(グテット公司制造,WSG-5型)中,将蒸馏水喷雾,经造粒、干燥工序,得到造粒物。在造粒物中添加10g硬脂酸镁,混合后,使用旋转型打片机(菊水制作所制造,クリ-ンプレスコレクト12型)进行压缩成形。成形条件和比较例1相同。实施例2
预先使用喷射磨机(日本二コ-マチック公司制造:PJM-1-1.5型)将乳糖(DMV公司:平均颗粒直径约80μm)粉碎,得到平均颗粒直径约15μm的乳糖。将1790g的该乳糖粉碎品、100g吗丁啉和100g交联聚维酮(ポリプテスドンXL-10:GAF公司)放入流动层造粒干燥机(グテット公司制造,WSG-5型)中,将蒸馏水喷雾,经造粒、干燥工序,得到造粒物。在造粒物中添加10g硬脂酸镁,混合后,使用旋转型打片机(菊水制作所制造,クリ-ンプレスコレクト12型)进行压缩成形。成形条件和比较例1相同。实施例3
使用在实施例1中得到的造粒物,在油压压力机(理研精机社制,P-1B型)的金属模(8mm直径、平型)和臼上预先涂布极少量的硬脂酸镁,以片剂重量200mg、压缩成形压力50Kg/cm2,得到片剂。实施例4
将140g实施例1使用的D-甘露糖醇粉碎品、10g吗丁啉、10g交联聚维酮(ポリプテスドンXL-10:GAF公司)和40g樟脑放入乙烯袋中,混合后,使用单发打片机(冈田精工社制造,N-20E型双压式粉末片剂机),金属模直径9mm,以压缩成形压力约1500Kg/cm2,得到片剂,片剂重量200mg。在真空干燥机中、在真空下于80℃将该片剂干燥10分钟。
接着,以试验例说明本发明片剂的片剂硬度和崩解时间。试验例
对实施例1、2和比较例1、2得到的片剂测定片剂硬度和崩解时间。使用片剂破坏强度测定机(富山产业制造:TH-203CP型)测定片剂硬度。另外,关于片剂的崩解时间,将片剂放置在10号金属网上,以4ml/min的速度从上部将水滴下,测定片剂从金属网上消失的时间,以该时间作为崩解时间。
评价结果示于表1中。
表1试料/压缩压力 150Kg 300Kg 450Kg 600Kg 800Kg比较例1 硬度 制片困难 制片困难 制片困难 1.9Kgf 2.3Kgf
崩解 - - - 20秒 22秒实施例1 硬度 1.9Kgf 3.9Kgf 5.1Kgf 6.2Kgf 7.3Kgf
崩解 10秒 15秒 16秒 19秒 27秒比较例2 硬度 制片困难 制片困难 制片困难 1.5Kgf 2.1Kgf
崩解 - - - 18秒 21秒实施例2 硬度 1.6Kgf 4.0Kgf 4.9Kgf 5.8Kgf 6.5Kgf
崩解 10秒 16秒 20秒 25秒 29秒
在比较例1和2中,至压缩成形压力450Kg成形是困难的,从600Kg渐渐能够成形。但是,成形物的硬度弱,还不能满足要求。在实施例1和2中,在压缩成形压力300Kg以上,得到足够的片剂硬度,并且,崩解时间也非常快速。以实施例1的压缩成形压力450Kg得到的片剂若实际服用,在口腔内在10秒就崩解。
对实施例3和4得到的各片剂也和上述同样地测定片剂硬度和崩解时间。其结果,实施例3得到的片剂具有硬度约为6.5Kgf的足够硬度,但崩解时间是约10秒。另外,实施例4得到的片剂的硬度是约4Kgf,在口腔内的崩解时间是约2秒,是非常快速的。
产业上的应用可能性
按照本发明能够提供在口腔内快速崩解的片剂。
Claims (8)
1、一种片剂,其含有平均颗粒直径30μm以下的糖醇或者糖类、活性成分和崩解剂。
2、如权利要求1所述的片剂,其含有对于1次给药分额为1~30mg的崩解剂。
3、如权利要求1或2所述的片剂,其中,所述糖醇是D-甘露糖醇。
4、如权利要求1或2所述的片剂,其中,所述糖类是乳糖。
5、如权利要求1~4所述的片剂,其中,所述崩解剂是交联聚维酮、羧甲基纤维素钠或者低取代度羟丙基纤维素。
6、一种片剂的制造方法,其特征在于,将含有平均颗粒直径30μm以下的糖醇或者糖类、活性成分和崩解剂的混合物压缩成形。
7、如权利要求6所述的片剂制造方法,其特征在于,在压缩成形时,预先将润滑剂涂布在打片机的捣杵和臼上,然后进行压缩成形。
8、如权利要求6所述的片剂制造方法,其特征在于,在易挥发的崩解助剂存在下,将含有平均颗粒直径30μm以下的糖醇或者糖类、活性成分和崩解剂的混合物压缩成形,然后使崩解助剂挥发。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP15355396 | 1996-06-14 | ||
JP153553/1996 | 1996-06-14 | ||
JP71107/1997 | 1997-03-25 | ||
JP7110797 | 1997-03-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1224349A true CN1224349A (zh) | 1999-07-28 |
CN1154479C CN1154479C (zh) | 2004-06-23 |
Family
ID=26412238
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB971955204A Expired - Lifetime CN1154479C (zh) | 1996-06-14 | 1997-06-12 | 口腔内快速崩解片剂 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20010014340A1 (zh) |
EP (2) | EP1598061B1 (zh) |
JP (4) | JP3797387B2 (zh) |
CN (1) | CN1154479C (zh) |
AT (2) | ATE297191T1 (zh) |
AU (1) | AU733032C (zh) |
CA (1) | CA2258159C (zh) |
DE (2) | DE69733476T2 (zh) |
DK (1) | DK0914818T3 (zh) |
EA (1) | EA001898B1 (zh) |
ES (1) | ES2243998T3 (zh) |
PT (1) | PT914818E (zh) |
WO (1) | WO1997047287A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1321629C (zh) * | 2002-02-15 | 2007-06-20 | 大塚制药株式会社 | 具有改善的压片特性的片剂及其生产方法 |
CN100342846C (zh) * | 1999-10-13 | 2007-10-17 | 协和发酵工业株式会社 | 压缩成形品及其制备方法 |
CN100490798C (zh) * | 2001-11-13 | 2009-05-27 | 协和发酵麒麟株式会社 | 含有l-谷氨酰胺和薁磺酸钠的速崩片剂或口腔内崩解片剂及其制造方法 |
CN102631289A (zh) * | 2004-10-28 | 2012-08-15 | 潘特克股份公司 | 高孔隙度的速崩固体剂型及其包括生产粉末和冻干步骤的制备方法 |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
JP3797387B2 (ja) * | 1996-06-14 | 2006-07-19 | 協和醗酵工業株式会社 | 口腔内速崩壊錠 |
US6024981A (en) * | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
EP1070496A4 (en) * | 1998-04-08 | 2004-07-21 | Kyowa Hakko Kogyo Kk | METHOD FOR PRODUCING TABLETS AND TABLET |
WO1999052492A1 (fr) * | 1998-04-10 | 1999-10-21 | Kyowa Hakko Kogyo Co., Ltd. | Comprime et procedes de fabrication de comprime |
ES2274625T3 (es) | 1998-05-18 | 2007-05-16 | Takeda Pharmaceutical Company Limited | Comprimidos desintegrables en la boca que comprenden un bencimidazol. |
AU743109B2 (en) | 1998-07-15 | 2002-01-17 | Asahi Kasei Kabushiki Kaisha | Excipient |
TW585786B (en) | 1998-07-28 | 2004-05-01 | Takeda Chemical Industries Ltd | Lansoprazole-containing rapidly disintegrable solid pharmaceutical composition |
US6368625B1 (en) * | 1998-08-12 | 2002-04-09 | Cima Labs Inc. | Orally disintegrable tablet forming a viscous slurry |
JP2000178204A (ja) * | 1998-10-05 | 2000-06-27 | Eisai Co Ltd | ホスフォジエステラ―ゼ阻害剤を含有する口腔内速崩壊性錠剤 |
FR2790387B1 (fr) | 1999-03-01 | 2001-05-18 | Prographarm Laboratoires | Comprime orodispersible presentant une faible friabilite et son procede de preparation |
KR20010006835A (ko) * | 1999-03-25 | 2001-01-26 | 김선진 | 경구용 속붕해정 |
CA2374760A1 (en) | 1999-06-18 | 2000-12-28 | Takeda Chemical Industries, Ltd. | Quickly disintegrating solid preparations |
JP2001058944A (ja) * | 1999-06-18 | 2001-03-06 | Takeda Chem Ind Ltd | 速崩壊性固形製剤 |
JP4817573B2 (ja) * | 1999-10-13 | 2011-11-16 | 協和発酵バイオ株式会社 | 圧縮成形物及びその製造方法 |
WO2001052820A1 (fr) * | 2000-01-17 | 2001-07-26 | Kyowa Hakko Kogyo Co., Ltd. | Pastille a effet moussant, pastille d'addition pour le bain a effet moussant, pastille detergente de lavage a effet moussant, pastille a effet moussant pour administration orale et procedes de production de ces pastilles |
CA2403594A1 (en) * | 2000-03-27 | 2002-09-18 | Kyowa Hakko Kogyo Co., Ltd. | Granules having good taking property |
US6316029B1 (en) * | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
JP4840549B2 (ja) * | 2000-11-20 | 2011-12-21 | トーアエイヨー株式会社 | 安定な血管拡張剤及びその製造方法 |
EP1226818A1 (en) * | 2001-01-26 | 2002-07-31 | Pfizer Products Inc. | Pharmaceutical dosage forms with enhanced cohesive and compressibility properties |
US20040122106A1 (en) * | 2001-03-06 | 2004-06-24 | Motohiro Ohta | Tablets quickly disintegrating in oral cavity |
AU2002238848B2 (en) * | 2001-03-06 | 2007-11-15 | Kyowa Hakko Kogyo Co., Ltd. | Use of a spray-dried powder comprising a sugar alcohol |
WO2002069934A1 (fr) * | 2001-03-06 | 2002-09-12 | Kyowa Hakko Kogyo Co., Ltd. | Préparations se délitant rapidement dans la bouche |
US9358214B2 (en) | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
CA2478101A1 (en) * | 2002-03-06 | 2003-09-12 | Kyowa Hakko Kogyo Co., Ltd. | Intraorally rapidly disintegrable tablets |
JPWO2003103713A1 (ja) * | 2002-06-10 | 2005-10-06 | 大日本製薬株式会社 | 速崩壊性錠剤及びその製造方法 |
EP1551457A1 (en) * | 2002-07-16 | 2005-07-13 | Elan Pharma International Limited | Liquid dosage compositions of stable nanoparticulate active agents |
DE10248652A1 (de) * | 2002-10-18 | 2004-04-29 | Solvay Interox Gmbh | Verfahren zur Herstellung von staubfreien Erdalkaliperoxiden |
FR2845914B1 (fr) * | 2002-10-18 | 2005-11-04 | Schwarz Pharma Lab | Compose antiemetique a desagregation rapide |
GB0226076D0 (en) | 2002-11-08 | 2002-12-18 | Rp Scherer Technologies Inc | Improved formulations containing substituted imidazole derivatives |
FI20022007A0 (fi) | 2002-11-08 | 2002-11-08 | Juvantia Pharma Ltd Oy | Oromukosaalinen valmiste ja menetelmä sen valmistamiseksi |
US8367111B2 (en) | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
JP4551627B2 (ja) * | 2003-02-28 | 2010-09-29 | 東和薬品株式会社 | 口腔内崩壊錠剤の製造方法 |
JP5584509B2 (ja) * | 2003-02-28 | 2014-09-03 | 東和薬品株式会社 | 口腔内崩壊錠剤 |
GB2404662A (en) * | 2003-08-01 | 2005-02-09 | Reckitt Benckiser | Cleaning composition |
US8545881B2 (en) * | 2004-04-19 | 2013-10-01 | Eurand Pharmaceuticals, Ltd. | Orally disintegrating tablets and methods of manufacture |
WO2005115342A1 (en) | 2004-05-24 | 2005-12-08 | Nycomed Pharma As | Particulate comprising a calcium-containing compound and a sugar alcohol |
US8216610B2 (en) * | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
JP2008500288A (ja) * | 2004-05-28 | 2008-01-10 | イメイジノット ピーティーワイ エルティーディー | 経口治療用化合物の供給系 |
TWI356713B (en) * | 2004-06-01 | 2012-01-21 | Nycomed Pharma As | Chewable, suckable and swallowable tablet containi |
US8747895B2 (en) | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
EP1802285B1 (en) * | 2004-10-21 | 2013-02-27 | Aptalis Pharmatech, Inc. | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
US20060105038A1 (en) * | 2004-11-12 | 2006-05-18 | Eurand Pharmaceuticals Limited | Taste-masked pharmaceutical compositions prepared by coacervation |
DE602006001295D1 (de) | 2005-02-03 | 2008-07-03 | Nycomed Pharma As | Schmelzgranulation einer zusammensetzung mit einer calziumhaltigen verbindung |
EA013867B1 (ru) | 2005-02-03 | 2010-08-30 | Никомед Фарма Ас | Способ получения гранулята, содержащего карбонат кальция |
US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
JP2009517346A (ja) * | 2005-11-28 | 2009-04-30 | イメイジノット ピーティーワイ エルティーディー | 治療用化合物の経口送達系 |
ATE479426T1 (de) | 2005-12-07 | 2010-09-15 | Nycomed Pharma As | Vorkompaktierte calciumhaltige zusammensetzungen |
UA95093C2 (uk) | 2005-12-07 | 2011-07-11 | Нікомед Фарма Ас | Спосіб одержання кальцієвмісної сполуки |
EP1965771A1 (de) * | 2005-12-21 | 2008-09-10 | ADD Advanced Drug Delivery Technologies, Ltd. | Pellets enthaltend einen kern mit einem wasserlöslichen träger |
FR2898492B1 (fr) * | 2006-03-15 | 2008-06-06 | Pierre Fabre Medicament Sa | Comprimes orodispersibles de domperidone |
KR101324898B1 (ko) * | 2006-03-31 | 2013-11-04 | 루비콘 리서치 피브이티. 엘티디. | 구강 붕해 정제 |
CA2661683C (en) | 2006-08-31 | 2015-11-24 | Eurand, Inc | Drug delivery systems comprising solid solutions of weakly basic drugs |
WO2008079342A2 (en) * | 2006-12-21 | 2008-07-03 | Mallinckrodt Inc. | Composition of and method for preparing orally disintegrating tablets |
CA2680536A1 (en) | 2007-03-13 | 2008-10-09 | Dainippon Sumitomo Pharma Co., Ltd. | Oral disintegrating tablet |
EP1977734A1 (en) * | 2007-04-03 | 2008-10-08 | Royal College of Surgeons in Ireland | A method of producing fast dissolving tablets |
JP4980144B2 (ja) * | 2007-06-05 | 2012-07-18 | 日機装株式会社 | 固型化透析用剤の製造方法 |
US20100292341A1 (en) * | 2007-06-29 | 2010-11-18 | Orchid Chemicals & Pharmaceuticals Limited | Quick dissolve compositions of memantine hydrochloride |
JP5537943B2 (ja) * | 2007-09-27 | 2014-07-02 | 田辺三菱製薬株式会社 | 速崩壊性固形製剤 |
US9314454B2 (en) * | 2007-12-28 | 2016-04-19 | Sawai Pharmaceutical Co., Ltd. | Oral cavity disintegrating tablet and method of producing the same |
BRPI0920599B1 (pt) | 2008-10-24 | 2021-10-19 | Toray Industries, Inc. | Comprimido estável contendo um derivado de 4,5-epoximorfinano |
EA021707B1 (ru) | 2008-11-17 | 2015-08-31 | Такеда Никомед Ас | Способ получения таблетки, содержащей по меньшей мере 50% мас./мас. карбоната кальция, и таблетка, полученная этим способом |
CN102988318A (zh) | 2008-11-25 | 2013-03-27 | 田边三菱制药株式会社 | 口腔速崩片及其制备方法 |
TR200903014A1 (tr) * | 2009-04-17 | 2010-11-22 | Sanovel İlaç San. Ve Ti̇c. A.Ş. | Oral yolla dağılan dimebolin bileşimleri. |
CA2940931C (en) | 2009-10-01 | 2019-04-30 | Adare Pharmaceuticals, Inc. | Orally administered corticosteroid compositions |
TWI603155B (zh) | 2009-11-09 | 2017-10-21 | 尼康股份有限公司 | 曝光裝置、曝光方法、曝光裝置之維修方法、曝光裝置之調整方法、以及元件製造方法 |
ES2739888T3 (es) | 2009-11-30 | 2020-02-04 | Adare Pharmaceuticals Inc | Composiciones y comprimidos farmacéuticos con recubrimiento compresible y métodos de fabricación |
EP2506836B1 (en) | 2009-12-02 | 2018-02-14 | Adare Pharmaceuticals S.R.L. | Fexofenadine microcapsules and compositions containing them |
TW201127375A (en) * | 2010-01-08 | 2011-08-16 | Eurand Inc | Taste masked topiramate composition and an orally disintegrating tablet comprising the same |
US8426461B2 (en) | 2011-01-17 | 2013-04-23 | Takeda Pharmaceutical Company Limited | Orally dispersible tablet |
CN103429223A (zh) * | 2011-01-17 | 2013-12-04 | 武田药品工业株式会社 | 口腔分散片 |
JP6061516B2 (ja) * | 2011-07-14 | 2017-01-18 | 協和発酵キリン株式会社 | ドンペリドン口腔内崩壊錠 |
JP6061924B2 (ja) | 2011-10-14 | 2017-01-18 | 武田薬品工業株式会社 | 口腔内分散性製剤 |
JP6004882B2 (ja) * | 2012-10-15 | 2016-10-12 | 三菱商事フードテック株式会社 | 圧縮成形に用いるためのマンニトール賦形剤及びこれを含有する錠剤 |
WO2015034678A2 (en) | 2013-09-06 | 2015-03-12 | Aptalis Pharmatech, Inc. | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis |
TWI777515B (zh) | 2016-08-18 | 2022-09-11 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2246013A1 (de) * | 1972-09-20 | 1974-03-28 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von poroesen tabletten |
IE45770B1 (en) | 1976-10-06 | 1982-11-17 | Wyeth John & Brother Ltd | Pharmaceutical dosage forms |
JPS5614098A (en) * | 1979-07-13 | 1981-02-10 | Takeda Chem Ind Ltd | Externally lubricating tablet making machine |
JPH0653658B2 (ja) | 1984-12-17 | 1994-07-20 | 中外製薬株式会社 | 安定な錠剤の製造法 |
JPH0774153B2 (ja) * | 1986-04-14 | 1995-08-09 | 三共株式会社 | ロキソプロフェン・ナトリウム含有製剤 |
JPS63162619A (ja) * | 1986-12-25 | 1988-07-06 | Teisan Seiyaku Kk | 遅溶性顆粒及びそれを用いた持続性複合顆粒 |
GB8710965D0 (en) * | 1987-05-08 | 1987-06-10 | Smith Kline French Lab | Pharmaceutical compositions |
KR960011236B1 (ko) * | 1987-05-08 | 1996-08-21 | 스미스 클라인 앤드 프렌취 라보라토리스 리미티드 | 제약학적 조성물 및 고체 제형 |
EP0349103B1 (en) * | 1988-05-04 | 1992-11-25 | Smith Kline & French Laboratories Limited | Chewable tablet |
GB8824392D0 (en) * | 1988-10-18 | 1988-11-23 | Ciba Geigy Ag | Dispersible formulation |
HU200926B (en) | 1988-10-28 | 1990-09-28 | Egyt Gyogyszervegyeszeti Gyar | Pharmaceutical composition comprising piroxicam and lactose for use in making tablets or capsules |
JP2781442B2 (ja) * | 1990-02-19 | 1998-07-30 | 旭化成工業株式会社 | 顆粒含有錠剤 |
JP2807346B2 (ja) | 1991-12-24 | 1998-10-08 | 山之内製薬株式会社 | 口腔内崩壊製剤及びその製造法 |
JP3069458B2 (ja) | 1992-01-29 | 2000-07-24 | 武田薬品工業株式会社 | 口腔内崩壊型錠剤およびその製造法 |
ATE210968T1 (de) | 1992-02-18 | 2002-01-15 | Nippon Shinyaku Co Ltd | Verfahren zur herstellung von schnelllöslicher tabletten und schnelllöslichen tablette beinhaltend xylitol |
GB9224855D0 (en) * | 1992-11-27 | 1993-01-13 | Smithkline Beecham Plc | Pharmaceutical compositions |
JP3797387B2 (ja) * | 1996-06-14 | 2006-07-19 | 協和醗酵工業株式会社 | 口腔内速崩壊錠 |
-
1997
- 1997-06-12 JP JP50144898A patent/JP3797387B2/ja not_active Expired - Lifetime
- 1997-06-12 WO PCT/JP1997/002032 patent/WO1997047287A1/ja active IP Right Grant
- 1997-06-12 DK DK97927372T patent/DK0914818T3/da active
- 1997-06-12 ES ES97927372T patent/ES2243998T3/es not_active Expired - Lifetime
- 1997-06-12 US US09/147,374 patent/US20010014340A1/en not_active Abandoned
- 1997-06-12 EP EP05012137A patent/EP1598061B1/en not_active Expired - Lifetime
- 1997-06-12 DE DE69733476T patent/DE69733476T2/de not_active Expired - Lifetime
- 1997-06-12 DE DE69739967T patent/DE69739967D1/de not_active Expired - Lifetime
- 1997-06-12 AU AU31895/97A patent/AU733032C/en not_active Expired
- 1997-06-12 AT AT97927372T patent/ATE297191T1/de active
- 1997-06-12 CA CA002258159A patent/CA2258159C/en not_active Expired - Lifetime
- 1997-06-12 AT AT05012137T patent/ATE477793T1/de not_active IP Right Cessation
- 1997-06-12 EA EA199900028A patent/EA001898B1/ru not_active IP Right Cessation
- 1997-06-12 CN CNB971955204A patent/CN1154479C/zh not_active Expired - Lifetime
- 1997-06-12 PT PT97927372T patent/PT914818E/pt unknown
- 1997-06-12 EP EP97927372A patent/EP0914818B1/en not_active Revoked
-
2005
- 2005-09-16 JP JP2005269822A patent/JP2006077018A/ja active Pending
-
2009
- 2009-07-31 JP JP2009179843A patent/JP2009256372A/ja active Pending
-
2012
- 2012-04-23 JP JP2012097573A patent/JP5484514B2/ja not_active Expired - Lifetime
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100342846C (zh) * | 1999-10-13 | 2007-10-17 | 协和发酵工业株式会社 | 压缩成形品及其制备方法 |
CN100490798C (zh) * | 2001-11-13 | 2009-05-27 | 协和发酵麒麟株式会社 | 含有l-谷氨酰胺和薁磺酸钠的速崩片剂或口腔内崩解片剂及其制造方法 |
CN1321629C (zh) * | 2002-02-15 | 2007-06-20 | 大塚制药株式会社 | 具有改善的压片特性的片剂及其生产方法 |
CN102631289A (zh) * | 2004-10-28 | 2012-08-15 | 潘特克股份公司 | 高孔隙度的速崩固体剂型及其包括生产粉末和冻干步骤的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
DE69733476D1 (de) | 2005-07-14 |
EP0914818B1 (en) | 2005-06-08 |
EA001898B1 (ru) | 2001-10-22 |
EP0914818A1 (en) | 1999-05-12 |
ATE297191T1 (de) | 2005-06-15 |
DE69733476T2 (de) | 2006-03-23 |
WO1997047287A1 (fr) | 1997-12-18 |
DK0914818T3 (da) | 2005-07-04 |
ATE477793T1 (de) | 2010-09-15 |
CA2258159C (en) | 2006-03-21 |
DE69739967D1 (de) | 2010-09-30 |
EA199900028A1 (ru) | 1999-06-24 |
AU733032C (en) | 2002-01-03 |
ES2243998T3 (es) | 2005-12-01 |
US20010014340A1 (en) | 2001-08-16 |
JP2009256372A (ja) | 2009-11-05 |
EP1598061B1 (en) | 2010-08-18 |
JP3797387B2 (ja) | 2006-07-19 |
CN1154479C (zh) | 2004-06-23 |
JP5484514B2 (ja) | 2014-05-07 |
AU3189597A (en) | 1998-01-07 |
PT914818E (pt) | 2005-08-31 |
JP2006077018A (ja) | 2006-03-23 |
EP0914818A4 (en) | 2001-03-14 |
JP2012167105A (ja) | 2012-09-06 |
CA2258159A1 (en) | 1997-12-18 |
EP1598061A1 (en) | 2005-11-23 |
AU733032B2 (en) | 2001-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1154479C (zh) | 口腔内快速崩解片剂 | |
CN1196476C (zh) | 口腔内快速崩解片剂的制造方法 | |
US8945618B2 (en) | Intrabuccally rapidly disintegrating tablet and a production method of the tablets | |
RU2189227C2 (ru) | Быстро распадающиеся прессованные в формах материалы и способ их получения | |
US5939091A (en) | Method for making fast-melt tablets | |
CN101283991B (zh) | 口腔崩解剂及其制造方法 | |
HUT76551A (en) | Quickly dispersing comestible unit and product | |
KR20030094272A (ko) | 구강내 급속 붕괴성 정제 | |
CN1170358A (zh) | 可咀嚼的剂型 | |
CN1198094A (zh) | 通过挤出含氢化异麦芽糖的聚合物/活性成分熔体可得到的固体剂型 | |
CN1440745A (zh) | 氟西汀药物制剂 | |
WO2002070013A1 (fr) | Utilisation d'une poudre sechee par atomisation contenant un alcool de sucre | |
CN1965836A (zh) | 口服固体制剂及其制备方法 | |
CN1742957A (zh) | 桑菊感冒泡腾片 | |
JP2000007555A (ja) | 錠剤およびこの錠剤の製造方法 | |
KR100481583B1 (ko) | 구강내에서빠르게붕괴하는정제 | |
JPH1112162A (ja) | 口腔内速崩錠及びその製造方法 | |
CN1528273A (zh) | 一种镇痛药盐酸曲马多口腔崩解片及其制备方法 | |
JP2005029557A (ja) | 口腔内速崩壊性錠剤およびその製造方法 | |
JP3637968B1 (ja) | 胃内崩壊性錠剤 | |
ES2349713T3 (es) | Comprimido rápidamente disgregable en cavidad oral. | |
CN1785374A (zh) | 一种滋补肝肾快速分散固体制剂及其制备方法 | |
CN100553614C (zh) | 口腔用固体速崩、速溶药物组合物及其片剂的制备方法 | |
CN1785398A (zh) | 一种坤顺快速分散固体制剂及其制备方法 | |
CN1160997A (zh) | 维生素和钙的单元盖仑氏片剂型治疗组合物及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: XIEHE FERMENTATION QILIN CO., LTD. Free format text: FORMER NAME: KYOWA HAKKO KOGYO CO., LTD. |
|
CP03 | Change of name, title or address |
Address after: Tokyo, Japan Patentee after: Kyowa Hakko Kirin Co., Ltd. Address before: Tokyo, Japan Patentee before: Kyowa Hakko Kogyo Co., Ltd. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20040623 |